Patogeneza zapaleń naczyń związanych z przeciwciałami przeciwko cytoplazmie neutrofilów

Łukasz Moos, Przemysław J. Kotyla

Abstrakt


ABSTRAKT

Zapalenia naczyń związane z przeciwciałami przeciwko cytoplazmie neutrofilów (antineutrophil cytoplasmic antibodies-associated vasculitis – AAV) to grupa chorób zajmujących małe naczynia i charakteryzujących się ich martwiczym zapaleniem oraz obecnością przeciwciał przeciwko cytoplazmie neutrofilów (antineutrophil cytoplasmic antibodies – ANCA) przy braku lub obecności jedynie skąpej ilości immunoglobulin w ścianie naczyń. Przeciwciała przeciwko cytoplazmie neutrofilów to przeciwciała klasy G skierowane przeciwko składnikom ziarnistości granulocytów obojętnochłonnych. Dowody na udział ANCA w patogenezie AAV pochodzą zarówno z obserwacji klinicznych, badań in vitro, jak i badań na zwierzętach. Przyczyny pojawiania się ANCA są cały czas wnikliwie badane, gdyż istnieje wiele nie w pełni zrozumiałych ścieżek patogenetycznych prowadzących do rozwoju choroby. Wciąż pojawiają się też nowe doniesienia pozwalające lepiej zrozumieć sposób powstawania patologicznych zmian wykrywanych u pacjentów z AAV.

W niniejszej pracy przedstawiono najbardziej prawdopodobne mechanizmy odpowiadające za powstawanie ANCA, jak również możliwą rolę przeciwciał w patogenezie rozwoju zapalenia naczyń.


Słowa kluczowe


przeciwciała przeciwko cytoplazmie neutrofilów; zapalenia naczyń

Pełny tekst:

PDF

Bibliografia


Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65(1):1-11. doi: 10.1002/art.37715.

Atisha-Fregoso Y, Hinojosa-Azaola A, Alcocer-Varela J. Localized, single organ vasculitis: clinical presentation and management. Clin Rheumatol 2013;32(1):1-6. doi: 10.1007/s10067-012-2069-2.

Hernandez-Rodriguez J, Hoffman GS. Updating single-organ vasculitis. Curr Opin Rheumatol 2012;24(1):38-45. doi: 10.1097/BOR.0b013e32834d8482.

Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 1982;285(6342):606.

van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1985;1(8426):425-9.

Noone D, Hebert D, Licht C. Pathogenesis and treatment of ANCA-asso­ciated vasculitis – a role for complement. Pediatr Nephrol 2018;33(1):1-11. doi: 10.1007/s00467-016-3475-5.

Cui Z, Zhao MH, Segelmark M, Hellmark T. Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int 2010;78(6):590-7. doi: 10.1038/ki.2010.198.

Xu PC, Cui Z, Chen M, Hellmark T, Zhao MH. Comparison of characteristics of natural autoantibodies against myeloperoxidase and anti-myeloperoxidase autoantibodies from patients with microscopic polyangiitis. Rheumatology (Oxford) 2011;50(7):1236-43. doi: 10.1093/rheumatology/ker085.

Roozendaal C, Pogány K, Horst G, Jagt TG, Kleibeuker JH, Nelis GF, et al. Does analysis of the antigenic specificities of anti-neutrophil cytoplasmic antibodies contribute to their clinical significance in the inflammatory bowel diseases? Scand J Gastroenterol 1999;34(11):1123-31.

Ooi CJ, Lim BL, Cheong WK, Ling AE, Ng HS. Antineutrophil cytoplasmic antibodies (ANCAs) in patients with inflammatory bowel disease show no correlation with proteinase 3, lactoferrin, myeloperoxidase, elastase, cathepsin G and lysozyme: a Singapore study. Ann Acad Med Singapore 2000;29(6):704-7.

Mahler M, Bogdanos DP, Pavlidis P, Fritzler MJ, Csernok E, Damoiseaux J, et al. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin Chim Acta 2013;424:267-73. doi: 10.1016/j.cca.2013.06.005.

Hervier B, Hamidou M, Haroche J, Durant C, Mathian A, Amoura Z. Systemic lupus erythematosus associated with ANCA-associated vasculitis: an overlapping syndrome? Rheumatol Int 2012;32(10):3285-90. doi: 10.1007/s00296-011-2055-z.

Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110(7):955-63. doi: 10.1172/JCI15918.

Schreiber A, Xiao H, Falk RJ, Jennette JC. Bone marrow-derived cells are sufficient and necessary targets to mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. J Am Soc Nephrol 2006;17(12):3355-64. doi: 10.1681/ASN.2006070718.

Little MA, Smyth L, Salama AD, Mukherjee S, Smith J, Haskard D, et al. Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. Am J Pathol 2009;174(4):1212-20. doi: 10.2353/ajpath.2009.080458.

Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990;87(11):4115-9.

Lu X, Garfield A, Rainger GE, Savage CO, Nash GB. Mediation of endothelial cell damage by serine proteases, but not superoxide released from antineutrophil cytoplasmic antibody-stimulated neutrophils. Arthritis Rheum 2006;54(4):1619-28. doi: 10.1002/art.21773.

Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009;20(2):289-98. doi: 10.1681/ASN.2008050497.

Kettritz R, Jennette JC, Falk RJ. Cross-linking of ANCA-antigens stimu­lates superoxide release by human neutrophils. J Am Soc Nephrol 1997;8(2):386-94.

Williams JM, Ben-Smith A, Hewins P, Dove SK, Hughes P, McEwan R, et al. Activation of the G heterotrimeric G protein by ANCA IgG F(ab′) 2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG. J Am Soc Nephrol 2003;14(3):661-9.

Eisenberger U, Fakhouri F, Vanhille P, Beaufils H, Mahr A, Guillevin L, et al. ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant 2005;20(7):1392-9. doi: 10.1093/ndt/gfh830.

Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004;93(4):398-401. doi: 10.1016/S1081-1206(10)61400-7.

Silva F, Specks U, Sethi S, Irazabal MV, Fervenza FC. Successful pregnancy and delivery of a healthy newborn despite transplacental transfer of antimyeloperoxidase antibodies from a mother with microscopic polyangiitis. Am J Kidney Dis 2009;54(3):542-5. doi: 10.1053/j.ajkd.2009.02.016.

Roth AJ, Ooi JD, Hess JJ, van Timmeren MM, Berg EA, Poulton CE, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Inves 2013;123(4):1773-83. doi: 10.1172/JCI65292.

Pendergraft WF 3rd, Niles JL. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol 2014;26(1):42-9. doi: 10.1097/BOR.0000000000000014.

Jones RB. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis. Nephron Clin Pract 2014;128(3-4):243-9. doi: 10.1159/000368580.

Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367(3):214-23. doi: 10.1056/NEJMoa1108735.

Popa ER, Stegeman CA, Kallenberg CG, Tervaert JW. Staphylococcus aureus and Wegener’s granulomatosis. Arthritis Res 2002;4(2):77-9. doi: 10.1186/ar392.

Laudien M, Gadola SD, Podschun R, Hedderich J, Paulsen J, Reinhold-Keller E, et al. Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener’s granulomatosis as compared to rheumatoid arthritis and chronic rhinosinusitis with nasal polyps. Clin Exp Rheumatol 2010;28(Suppl. 57):51-5.

Heal JR, Roberts GW, Raynes JG, Bhakoo A, Miller AD. Specific interactions between sense and complementary peptides: the basis for the proteomic code. Chembiochem 2002;3(2-3):136-51.

Pendergraft WF 3rd, Preston GA, Shah RR, Tropsha A, Carter CW Jr, Jennette JC, et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to the autoantigen proteinase-3. Nat Med 2004;10(1):72-9. doi: 10.1038/nm968.

Kain R, Exner M, Brandes R, Ziebermayr R, Cunningham D, Alderson CA, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008;14(10):1088-96. doi: 10.1038/nm.1874.

Roth AJ, Brown MC, Smith RN, Badhwar AK, Parente O, Chung HC, et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol 2012;23(3):545-55. doi: 10.1681/ASN.2011030273.

Tadema H, Heeringa P, Kallenberg CG. Bacterial infections in Wegener’s granulomatosis: mechanisms potentially involved in autoimmune pathogenesis. Curr Opin Rheumatol 2011;23(4):366-71. doi: 10.1097/BOR.0b013e328346c332.

Holle JU, Windmöller M, Lange C, Gross WL, Herlyn K, Csernok E. Toll-like receptor TLR2 and TLR9 ligation triggers neutrophil activation in granulomatosis with polyangiitis. Rheumatology (Oxford) 2013;52(7):1183-9. doi: 10.1093/rheumatology/kes415.

De la Cruz-Hernández E, Perez-Plasencia C, Pérez-Cardenas E, Gonzalez-Fierro A, Trejo-Becerril C, Chávez-Blanco A, et al. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma. Oncol Rep 2011;25(2):399-407. doi: 10.3892/or.2010.1086.

von Schmiedeberg S, Goebel C, Gleichmann E, Uetrecht J. Neutrophils and drug metabolism. Science 1995;268(5210):585-6.

Berthelot JM, Le Goff B, Neel A, Maugars Y, Hamidou M. NETosis: At the crossroads of rheumatoid arthritis, lupus, and vasculitis. Joint Bone Spine 2017;84(3):255-62. http://dx.doi.org/10.1016/j.jbspin.2016.05.013.

Metzler KD, Goosmann C, Lubojemska A, Zychlinsky A, Papayannopoulos V. A myeloperoxidase-containing complex regulates neutrophil elastase release and actin dynamics during NETosis. Cell Rep 2014;8(3):883-96. doi: 10.1016/j.celrep.2014.06.044.

Nakazawa D, Tomaru U, Suzuki A, Masuda S, Hasegawa R, Kobayashi T, et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: Implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheum 2012;64(11):3779-87. doi: 10.1002/art.34619.

Sangaletti S, Tripodo C, Chiodoni C, Guarnotta C, Cappetti B, Casalini P, et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood 2012;120(15):3007-18. doi: 10.1182/blood-2012-03-416156.

Kessenbrock K, Krumbholz M, Schönermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009;15(6):623-5. doi: 10.1038/nm.1959.

Jenette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 1989;135:921-30.

Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007;170(1):52-64. doi: 10.2353/ajpath.2007.060573.

Huugen D, van Esch A, Xiao H, Peutz-Koostra CJ, Buurman WA, Tervaert JW, et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 2007;71(7):646-54. doi: 10.1038/sj.ki.5002103.

Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004;350(6):552-9. doi: 10.1056/NEJMoa031688.

Hillmen P, Neal S, Young NS, Schubert J, Brodsky RA, Socié G, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355(12):1233-43. doi: 10.1056/NEJMoa061648.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368(23):2169-81. doi: 10.1056/NEJMoa1208981.

Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: A study of 126 cases. Kidney Int 2004;65(6):2145-52. doi: 10.1111/j.1523-1755.2004.00632.x.

Gou SJ, Yuan J, Chen M, Yu F, Zhao MH. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 2013;83(1):129-37. doi: 10.1038/ki.2012.313.

Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 2014;25(2):225-31. doi: 10.1681/ASN.2013020143.

Jayne DR, Bruchfeld A, Schaier M, Ciechanowski K, Harper L, Jadoul M, et al. Oral C5a receptor antagonist CCX168 phase II clinical trial in ANCA-associated renal vasculitis. Ann Rheum Dis 2014;73 Suppl 2:148.

Jayne D, Bruchfeld A, Harper L, Schaier M, Venning M, Hamilton P, et al. Successful steroid replacement in ANCA-associated vasculitis with C5a receptor inhibitor CCX168 in phase 2 randomised trial (CLEAR). Nephrol Dial Transplant 2016;31 Suppl 1:i45-i47.

Jennette JC, Falk RJ. B-cell mediated pathogenesis of ANCA-mediated vasculitis. Semin Immunopathol 2014;36(3):327-38. doi: 10.1007/s00281-014-0431-y.

Morgan MD, Day CJ, Piper KP, Khan N, Harper L, Moss PA, et al. Patients with Wegener’s granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology 2010;130(1):64-73. doi: 10.1111/j.1365-2567.2009.03213.x.

Free ME, Bunch DO, McGregor JA, Jones BE, Berg EA, Hogan SL, et al. Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum 2013;65(7):1922-33. doi: 10.1002/art.37959.

Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW. Differential B- and T-cell activation in Wegener’s granulomatosis. J Allergy Clin Immunol 1999;103:885-94.

Culton DA, Nicholas MW, Bunch DO, Zhen QL, Kepler TB, Dooley MA, et al. Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance loss. J Clin Immunol 2007;27(1):53-68. doi: 10.1007/s10875-006-9051-1.

Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, et al. Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol 2013;8(3):382-91. doi: 10.2215/CJN.03950412.

Scapini P, Bazzoni F, Cassatella MA. Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils. Immunol Lett 2008;116(1):1-6. doi: 10.1016/j.imlet.2007.11.009.

Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, Meinl E. BAFF is elevated in serum of patients with Wegener’s granulomatosis. J Autoimmun 2005;25(4):298-302. doi: 10.1016/j.jaut.2005.08.004.

Nagai M, Hirayama K, Ebihara I, Shimohata H, Kobayashi M, Koya­ma A. Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activity. Nephron Clin Pract 2011;118(4):c339-45. doi: 10.1159/000323393.

Bader L, Koldingsnes W, Nossent J. B-lymphocyte activating factor levels are increased in patients with Wegener’s granulomatosis and inversely correlated with ANCA titer. Clin Rheumatol 2010;29(9):1031-5. doi: 10.1007/s10067-010-1526-z.




DOI: http://dx.doi.org/10.21164/pomjlifesci.373

Copyright (c) 2018 Łukasz Moos, Przemysław J. Kotyla

URL licencji: https://creativecommons.org/licenses/by-nc-nd/3.0/pl/